Correspondence 0001493152-24-020906 from Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: May 21, 2024 · CIK: 0001642380 · Accession: 0001493152-24-020906
AI Filing Summary & Sentiment
File numbers found in text: 333-279350
Letter
Oncocyte Corporation
Cushing
Irvine, California 92618
May 21, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Jessica Dickerson
Re: Oncocyte Corporation
Registration Statement on Form S-3
Originally filed on May 10, 2024, as amended on May 17, 2024
File No. 333-279350 (the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Oncocyte Corporation (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on May 22, 2024, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Greg Kramer, Esq. at (212) 835-4819.
Very
truly yours,
Oncocyte
Corporation
Show Raw Text
CORRESP
1
filename1.htm
Oncocyte
Corporation
15
Cushing
Irvine,
California 92618
May
21, 2024
VIA
EDGAR
Division
of Corporation Finance
Office
of Life Sciences
U.S.
Securities and Exchange Commission
Washington,
D.C. 20549
Attention:
Jessica Dickerson
Re:
Oncocyte
Corporation
Registration
Statement on Form S-3
Originally
filed on May 10, 2024, as amended on May 17, 2024
File
No. 333-279350 (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under
the Securities Act of 1933, as amended, Oncocyte Corporation (the “Company”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on May 22, 2024, or
as soon thereafter as practicable.
Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes
and Boone, LLP, attention: Greg Kramer, Esq. at (212) 835-4819.
Very
truly yours,
Oncocyte
Corporation
By:
/s/
Josh Riggs
Josh
Riggs
President
and Chief Executive Officer
cc:
Greg Kramer, Esq., Haynes and Boone, LLP